Anakinra Potentiates the Protective Effects of Etanercept in Transplantation of Marginal Mass Human Islets in Immunodeficient Mice
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Anti-inflammatory agents are used routinely in clinical islet transplantation in an attempt to promote islet engraftment. Infliximab, and more recently etanercept, is being used to neutralize tumor necrosis factor alpha, but this tenet is based on limited preclinical data. One group has promoted the potential of combined etanercept with an IL-1 receptor antagonist, anakinra in a small clinical study, but without strong preclinical data to justify this approach. We therefore sought to evaluate the impact of combined anakinra and etanercept in a marginal islet mass transplant model using human islets in immunodeficient mice. The combination of anakinra and etanercept led to remarkable improvement in islet engraftment (control 36.4%; anakinra 53.9%; etanercept 45.45%; anakinra and etanercept 87.5% euglycemia, p < 0.05 by log-rank) compared to single-drug treated mice or controls. This translated into enhanced metabolic function (area under curve glucose tolerance), improved graft insulin content and marked reduction in beta-cell specific apoptotis (0.67% anakinra + etanercept vs. 23.5% control, p < 0.001). These results therefore strongly justify the combined short-term use of anakinra and etanercept in human islet transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Inflammatory mediators and islet ?-cell failure: a link between type 1 and type 2 diabetes
Donath, M. Y., St�rling, J., Maedler, K., & Mandrup-Poulsen, T. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0450-y · Cited by 422
Biarnés, M., Montolio, M., Nacher, V., Raurell, M., Soler, J., & Montanya, E. (2002) · Diabetes · doi:10.2337/diabetes.51.1.66 · Cited by 420 · cited 1×
“Preventing the action of these cytokines on transplanted islets has therefore been hypothesized to protect the engrafting b-cell mass in the early posttransplant period, where over 60% of the infused islet mass is destroyed within hours to days posttransplant (33,34).”
Background
Cited by
Clinical pancreatic islet transplantation
Shapiro, A. M. J., Pokrywczynska, M., & Ricordi, C. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.178 · Cited by 747
Self-citationPancreatic Islet Transplantation in Humans: Recent Progress and Future Directions
Rickels, M. R., & Robertson, R. P. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00154 · Cited by 329
Update on Islet Transplantation
McCall, M., & James Shapiro, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007823 · Cited by 226
Self-citationAdvances in Islet Transplantation and the Future of Stem Cell–Derived Islets to Treat Diabetes
Kieffer, T. J., Hoesli, C. A., & Shapiro, A. M. J. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041624 · Cited by 7
Self-citation
Metadata
- Authors
- McCall, M., Pawlick, R., Kin, T., & Shapiro, A. M. J.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 12
- Issue
- 2
- Pages
- 322-329
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W1602219465
- Cited by
- 93
- References
- 3
- FWCI
- 8.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anakinra Potentiates the Protective Effects of Etanercept in Transplantation of Marginal Mass Human Islets in Immunodeficient Mice. https://app.cochat.ai/papers/10.1111/j.1600-6143.2011.03796.x
- The paper
- McCall, M., Pawlick, R., Kin, T., & Shapiro, A. M. J. (2012). Anakinra Potentiates the Protective Effects of Etanercept in Transplantation of Marginal Mass Human Islets in Immunodeficient Mice. American Journal of Transplantation. https://doi.org/10.1111/j.1600-6143.2011.03796.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.